论文部分内容阅读
目的:探讨促性腺激素释放激素类似物(GnRHa)与重组人生长激素(rhGH)联合治疗小儿特发性中枢性性早熟(ICPP)的价值。方法:选择2011年4月至2013年10月化州市妇幼保健院收治的60例ICPP患儿作为研究对象,随机分为观察组(GnRHa联合rhGH治,30例)和对照组(单纯GnRHa治疗,30例)。随访观察1年,比较两组患儿身高变化情况及不良反应发生率。结果:与治疗前和对照组治疗后比较,观察组预测成年身高、年生长速度及按骨龄的身高标准差分值(HtSDS)均显著增高,差异有统计学意义(P<0.05)。两组局部疼痛、炎症、轻度过敏及红斑发生率比较,差异无统计学意义(P>0.05)。结论:GnRHa联合rhGH治疗能显著改善ICPP患儿预测成年身高和生长速度,且联合治疗并不显著增加不良反应发生率,安全性高。
Objective: To investigate the value of GnRHa in combination with recombinant human growth hormone (rhGH) in the treatment of children with idiopathic central precocious puberty (ICPP). Methods: From April 2011 to October 2013, 60 cases of ICPP children admitted to Huazhong MCH hospital were randomly divided into observation group (GnRHa combined with rhGH treatment, 30 cases) and control group (GnRHa treatment alone) , 30 cases). Followed up for 1 year, compared the height changes and the incidence of adverse reactions in both groups. Results: Compared with the control group before and after treatment, the height, the annual growth rate and the standard deviation height (HtSDS) of the observation group were significantly increased (P <0.05). The two groups of local pain, inflammation, mild allergies and erythema incidence, the difference was not statistically significant (P> 0.05). Conclusion: GnRHa combined with rhGH can significantly improve the prediction of adult height and growth rate in children with ICPP, and the combined treatment does not significantly increase the incidence of adverse reactions, and high safety.